ONCY:NASDAQOncolytics Biotech Inc. analysis
Data as of Oct 20, 2026 - not real-time
- Latest price
- $0.50
- Risk: high
- 9/10High risk
Summary
At $0.4963, Oncolytics Biotech Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. Across the trailing 30 sessions it lost 40.5%. Relative strength is 30.3 — approaching oversold — and the MACD signal is bearish. Price has been bracketed by support at $0.4400 and resistance at $0.7800.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 747.1% above the current quote.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 83.5%, a beta of 1.72 and a maximum drawdown of 63.0%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 88 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 1/10 long-term conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Sell-side targets cluster 747.1% above the current quote.
On a 1-10 scale the risk profile lands at 9 — high. With 30-day volatility of 83.5%, a beta of 1.72 and a maximum drawdown of 63.0%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 88 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 1/10 long-term conviction.
Top market events
- By David Bautz, PhD NASDAQ: ONCY READ THE FULL ONCY RESEARCH REPORT Business Update Alignment Reached with FDA on...
- Data support pelareorep’s potential as a backbone therapy to transform immunologically inactive liver tumors into a...
- Thursday, Oncolytics Biotech Inc. ONCY announced encouraging preclinical results, evaluating pelareorep in combination...
Market outlook
Short term
< 1 yearCautious
Model confidence4/104 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.89
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.89
- Analyst targets imply +747.1% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +747.1% versus the current price
- Negative free cash flow
- 30-day volatility of 83.5%
Key metrics
Financial health
P/E Ratio-2.5
ROA-211.24%
P/B Ratio-10.1
Op. Cash Flow$-26704000
Free Cash Flow$-12010852
Industry P/E31.3
Technical analysis
TrendBearish
RSI30.3
Support$0.44
Resistance$0.78
MA 20$0.60
MA 50$0.73
MA 200$0.89
MACDBearish
VolumeIncreasing
Fear & Greed Index87.98
Valuation
Target Price$4.20
Upside/Downside747.10%
GradeFair
TypeBlend
Risk assessment
Beta1.72
Volatility83.47%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.